Kornimate/medical-research-clean huggingface dataset:
clinical trial of the tqb3602 capsule combined with ak105 injection in patients with advanced cancers

Conditions: Advanced Cancers

Summary: tqb3602 is a kind of proteasome inhibitor, ak105 is an anti-programmed cell death protein 1 (pd-1) antibody.


Eligibility criteria:
inclusion criteria: * 1 evidence of a personally signed and dated informed consent document indicating that the patient has been informed of all pertinent aspects of the study. * 2 age ≥ 18; eastern cooperative oncology group perfomance status score: 0-2; at least 3 months expected survival period. * 3 subjects with relapse advanced malignant solid tumors clearly diagnosed by pathology and / or cytology, lack of conventional effective treatment methods, failure or relapse after treatment. * 4 resolved acute effects of any prior therapy to baseline severity or grade ≤ 1 per ctcae v5.0 except for aes not constituting a safety risk by investigator judgment. * 5 must have adequate organ and bone marrow function. * 6 male and female patients of childbearing potential and at risk for pregnancy must agree to use two highly effective method(s) of contraception throughout the study and for at least 6 months after the last dose of assigned treatment. exclusion criteria: * 1 subjects with other malignancies currently or suffered within 3 years. the following two conditions can be enrolled: other malignant tumors treated with a single operation to achieve disease-free survival (dfs) for 5 consecutive years; cured cervical carcinoma in situ, non-melanoma skin cancer and superficial bladder tumors\[ ta (non-invasive tumor), tis (carcinoma in situ) and t1 (tumor infiltrating basement membrane)\]; * 2 sujects with multiple factors affecting oral administration； * 3 subjets with unhealed toxicity above grade 1 common terminology criteria for adverse events version 5.0 due to previous antitumor treatment； * 4 subjects who have received major surgical treatment, open biopsy or obvious traumatic injury within 4 weeks before first administration； * 5 subjects who have received surgery, chemotherapy, radiotherapy or other anticancer therapies 4 weeks before the first administration.
chevron osteotomy versus scarf osteotomy in the treatment of hallux valgus

Conditions: Hallux Valgus

Summary: comparison between two techniques of osteotomy wich are more or less invasive : two criterias : clinical data and x-rays data. all patients operated for hallux valgus for 01/01/99 to 31/12/03 in the department of bone surgery chu limoges : * scarf or jonhson (chevron) osteotomy * experienced surgeon : pr arnaud, pr mabit or pr charissoux.

prospective assessmentfor all patients with an average follow up of 5 years : * groulier score scale (similar to aofas score rating) * x-rays data * clinical evaluation * pedoscopic data.

Eligibility criteria:
inclusion criteria: * all patients operated for hallux valgus for 01/01/99 to 31/12/03 in the department of bone surgery chu limoges. * scarf or johnson (chevron) osteotomy, * experienced surgeon : pr mabit, pr arnaud, pr charissoux. * age of patients \> 18 years. exclusion criteria: * hallux valgus wich wasn't operated by these surgeons. * no consentment

Keywords: scarf osteotomy chevron osteotomy comparison
evaluation of shell technique in secondary alveolar cleft grafting

Conditions: Alveolar Cleft; Alveolar Ridge Cleft

Summary: this study aims to evaluate the sufficiency of khoury shell technique for reconstruction of alveolar cleft. khoury technique was carried out using cortical bone shell fixed away from alveolar bone using two micro-screws, which was harvested from anterior iliac bone crest. the gap between the shell cortical bone and the native alveolar bone was filled by cancellous bone which was harvested from anterior iliac crest bone. the whole graft was covered by collagen membrane. the volumetric bone gain of the defect was determined via cbct.


Eligibility criteria:
inclusion criteria: 1. patients with alveolar ridge cleft 2. males and females 7-14 years of age. 3. patients with adequate oral hygiene. 4. compliance with all requirements in the study and signing the informed consent. exclusion criteria: 1. patients with diseases of the immune system or any medical condition that may influence the outcome (uncontrolled diabetes, glycated hemoglobin- hba1c ≥ 7%). 2. patients with systemic disease affecting bone healing. 3. patients who are chronic users of medications known to affect the periodontal status (calcium antagonists, anti-convulsives, immunosuppressives, anti-inflammatory medications). 4. patients with history of intravenous and/or oral bisphosphonate use. 5. pathologic lesions or acute infection in the area of defect. 6. patients with poor oral hygiene that are not amenable to motivation and improvement. 8. vulnerable patients.

Keywords: alveolar ridge cleft khoury shell technique 3d alveolar ridge reconstruction anterior iliac crest bone graft
prognostic value of plasma dpp4 activity in st-elevation myocardial infarction patients

Conditions: Coronary Angiography; Dipeptidyl Peptidase 4

Summary: increased plasma dpp4 activity (dpp4a) could predict both subclinical and new-onset atherosclerosis, and our previous study has found that the dpp4a was significantly lower in mi patients compared with patients having chest pain or unstable angina alone, and dpp4a is associated with no-reflow and major bleeding events in stemi patients during hospital stay. as no-reflow phenomenon and major bleeding events independently associates with a worse in-hospital and long-term prognosis. one may speculate that the dpp4a is associated with long-term follow-up adverse cardiovascular events in these patients.the hypothesis was tested in this study.


Eligibility criteria:
inclusion criteria: * consecutive patients of acute stemi come to our department,absent of cardiogenic shock, and survival for at least 24 h after pci treatment. exclusion criteria: * patients with cancer, and patients who were taking a dpp4 inhibitoror a glucagon-like peptide-1 (glp-1) analogue
influence of hormone treatment in radiation therapy for bladder cancer

Conditions: Bladder Cancer; Radiation Therapy Complication; Quality of Life

Summary: bladder cancer is often treated with cystectomy or radiation therapy. following radiation therapy patients will often have severe side effects from the treatment. studies have suggested that simultanously treatment with androgen deprivation therapy during radiation therapy may be able to proctect stemcells in the bladder, thus improving tissue recovering post-radiation, which would result in improved bladder compliance following the treatment and ultimately result in fewer side effects and overall improved patient quality of life.

bladder cancer (bc) is one of the most frequent cancers in the world and more common in men than female. gender-related factors may be involved in the pathogenesis of bc. studies have suggested that androgen-receptors may be present in the bladder and potentially involved in bc aetiology, thus making bc susceptible for androgen deprivation therapy (adt). currently treatment for bc includes surgery or radiation therapy. adt include degarelix, which besides decreasing testosterone, has been shown to reduce the occurrence of bc in rats and promote stem cell recovery following radiation therapy. hypothesis adt will lower the incidence of bc, and the prognosis of bc will vary depending on the type of adt used. furthermore degarelix administered during radiation therapy for bc will reduce the degree of fibrosis in the bladder thus decreasing adverse side effects. methods a cohort of patients treated with adt for pc will be compared to two cohorts of age-matched men with and without pc both without adt. the incidence of bc will be recorded for every group. furthermore the cohort of patients with pc and adt will be divided into subgroups, depending of the type of adt they have received and the degree of deprivation. they will be compared in terms of incidence and prognosis of bc. finally, a small pilot study will be conducted to investigate the effect of degarelix when administered during radiation therapy for bc. perspectives this will be one of the largest studies to investigate the potential influence of sex hormones in the development and prognosis of bc and potentially lead to new treatment options and possibly a new way of reducing radiation side effects.

Eligibility criteria:
inclusion criteria: * t2-t4 bladder cancer * radiation therapy * able to fill out questionnaires * signed informed consent exclusion criteria: * kad prior to tur-b * dementia or other cognitive impairment * metastatic disease
gretel: tumor response to standard radiotherapy and tmz patients with gbm

Conditions: Glioblastoma; Glioma, Malignant

Summary: the purpose of this study is to better define longitudinal genomic alterations in patients with glioblastoma (gbm), and to determine if plasma circulating tumor dna (ctdna) or cell free dna (cfdna) is associated with disease recurrence, survival, tumor characteristics, and/or peripheral immunosuppression.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years * patients newly diagnosed with malignant glioma, idh wildtype who have undergone surgical resection for their tumor and who are planned for standard of care radiation therapy with concurrent temozolomide (i.e., at least 59 gy in 30 fractions over 6 weeks) * patients must have leftover tissue available from the surgical resection of their tumor available to request for this research. * able to undergo mri of brain with and without contrast * signed informed consent approved by the institutional review board (irb) exclusion criteria: * prior, unrelated malignancy requiring current active treatment with the exception of cervical carcinoma in situ and adequately treated basal cell or squamous cell carcinoma of the skin

Keywords: khasraw glioblastoma glioma pro00110247 gretel duke
long term quality of life in melanoma patients in netherlands

Conditions: Melanoma

Summary: study of late physical, psychological and social effects in patients treated with ipilimumab for advanced (stage iv or unresectable stage iii) melanoma.


Eligibility criteria:
inclusion criteria- * patient population: adults ≥ 18 years of age at diagnosis, diagnosed with histologically confirmed advanced (stage iv or unresectable stage iii) melanoma, who have received at least one course of ipilimumab treatment (first, second, or second plus line; routine practice or study treatment) in one of the specified treatment centers, and who have survived at least 2 years after (completion of) ipilimumab treatment (measured from last ipilimumab administration) * matched healthy control population: individuals without melanoma (stage iii or iv) diagnosis that have been included in the profiles cohort exclusion criteria * insufficient understanding of the dutch language * other anticancer treatment after ipilimumab or during study entry * disease recurrence during the study other protocol defined inclusion/exclusion criteria could apply
moving cupping for plaque psoriasis: a randomized controlled trial

Conditions: Plaque Psoriasis

Summary: the purpose of this study was to provide evidence support for the effectiveness and safety of moving cupping therapy for plaque psoriasis through clinical studies.

psoriasis is a common chronic and recurrent inflammatory skin disease. the incidence of the disease is increasing year by year, seriously affecting people's quality of life. the systematic treatment of psoriasis in modern medicine is limited of wide application due to the adverse reactions of different degrees and the high economic cost. complementary and alternative medicine (cam) therapies have become an increasingly visible part of dermatology. cupping is becoming an important therapy in complementary and alternative medicine. although, moving cupping therapy has been widely used in the treatment of plaque psoriasis and has been recognized by a large number of peers and patients, but still lacks high-quality evidence-based medical evidence. therefore, the project team intends to provide evidence support for the effectiveness and safety of moving cupping therapy for plaque psoriasis through clinical studies.

Eligibility criteria:
inclusion criteria: 1. diagnostic criteria for plaque psoriasis; 2. skin lesions involve ≤10% bsa (the lesions are mainly located in the torso / limbs, palm / sole, face / scalp, vulva area is not included); 3. aged between 18 and 65 years. 4. consent to participate in the research study and sign the informed consent form exclusion criteria: 1. patients with pustular psoriasis, arthropathic, erythroderma psoriasis and / or drip psoriasis; 2. plaque psoriasis patients with bsa\>10%; 3. any clinically active skin diseases other than moderate to severe psoriasis vulgaris which might counter or influence the study aim; 4. patients who used any of the following systemic treatments within 4 weeks before the baseline visit e.g.: drugs for other studies, immuno-suppressive drugs, biologics; 5. patients who used topical treatment within 2 weeks before the baseline visit e.g. corticosteroids ultraviolet-light therapy including sunbathing; 6. active infectious disease which was hard to control; 7. history of severe systemic disease. or the clinical test index is one of the following: the alt or the ast is higher than 1.5 times; any of the main routine blood indexes (wbc, rbc, hb, plt) is lower than the limit of normal; or other laboratory abnormalities and patients were judged not to be suitable for this study; 8. family history of cancer-prone patients; 9. patients with immunocompromised and can cause skin allergies and infection when moving cupping; 10. pregnant or lactating women; 11. patients with a history of alcohol abuse and drug abuse; 12. have a history of serious mental illness or family history; 13 other reasons researchers believe that patients are not suitable for this study.

Keywords: plaque psoriasis blood stasis syndrome randomized controlled trial moving cupping
application of magnetic resonance fat-free imaging

Conditions: Sarcoma

Summary: magnetic resonance imaging (mri) is presently the best study for assessing the size and extent of the patient's sarcoma. many sarcomas contain fat that can interfere with the accuracy of sarcoma detection. the investigators have developed a new mri method that can suppress all the fat signals in the patient's tumor and this may improve the investigators' ability to see the patient's sarcoma. the purpose of this study is to determine if the investigators' new fat-free imaging methods provides them with images that are better than, equal to, or worse than those images obtained by standard mri methods. this study may help the investigators develop a more accurate mri examination.

in addition, we will perform the same scans on 4 volunteers who have no history of sarcoma. scanning volunteers will allow us to optimize the imaging technique by 1.) determine the best combination of pulse-sequence and magnetization transfer technique to obtain the greatest contrast and 2.) determine the parameters of repetition time (tr), echo time (te) and magnetization transfer time and power in order to reduce overall image acquisition time while optimizing image quality. honing this technique on volunteers will allow us to decrease scan time and potential discomfort for patients.

Eligibility criteria:
inclusion criteria: * participant is capable of providing verbal consent. * 18 years of age or older. * participants will belong to one of the following two categories: * patient with a known or suspected soft tissue sarcoma of the extremity or trunk who is/will be scheduled for an mri scan as part of their routine care, -or-- * volunteer with no history of sarcoma.

Keywords: sarcoma soft tissue mri questionnaire 09-078
effect of intrathoracic pressure regulation on decreased cerebral perfusion

Conditions: Head Injury; Intracranial Pathology; Compromised Cerebral Perfusion

Summary: the purpose of the study is to evaluate the physiological response to application of the intrathoracic pressure regulator (itpr) in patients with compromised cerebral circulation. the study will evaluate the physiological response to intrathoracic pressure regulation (ipr) therapy in hemodynamically stable patients with compromised cerebral circulation who are on ventilatory support.


Eligibility criteria:
inclusion criteria: * ≥18 years of age * intubated and mechanically ventilated on a volume controlled mode * head injury or other intracranial pathology and compromised cerebral perfusion * arterial line in place or alternative with continuous pressure monitoring * spo2 ≥90% * mean arterial pressure \>55 * admission to icu or about to undergo neurosurgery with planned placement of an invasive intracranial pressure monitor * inclusion presents no significant delays to planned emergent neurosurgery * prior written informed consent exclusion criteria: * cardiac or pulmonary injury * confirmed pneumothorax or hemothorax * serious neck injury resulting in neck swelling with jugular venous compression * evidence of ongoing uncontrolled bleeding * respiratory disease such as copd, interstitial lung disease, or other parenchymal or pulmonary vascular disease * marked hypertension at time of device use defined as systolic blood pressure \>180 mmhg * congestive heart failure * women with positive serum or urine pregnancy test or breast feeding

Keywords: itpr cpp tbi traumatic brain injury cerebral perfusion pressure intrathoracic pressure regulator
the effects of mirror therapy on upper extremity in stroke patients

Conditions: Cerebrovascular Accident

Summary: the purpose of this study is to compare treatment efficacy of mirror therapy (mt), mirror therapy combining mesh glove (mg+mt) stimulation, and controlled treatment (ct) in people with stroke.

55% to 75% of people after stroke have a paretic arm that causes motor impairment. among novel rehabilitation interventions, mt was found to be beneficial and comparatively low-cost. mt reduced motor impairment possibly in part of recruiting the premotor cortex or balancing the neural activation within the primary motor cortex toward the affected hemisphere. however, the benefits in certain aspects of outcomes are under debate. another treatment, mg, can be used to normalize muscle tone, suppress muscle spasticity, enhance residual volitional activity of hand and arm, or even increasing walking speed. in addition, providing mg stimulation might result in plastic changes in the primary motor cortex, and induced a long-lasting modulated effect on motor cortical excitability. the possible mechanism of brain plasticity underlying mg is collective with the mechanism behind the mt. adding mg to mt might augment the cortical reorganization. in sum, combining mt with mg may supplement the disadvantage or uncertain effects of mt and broaden the benefited outcomes.

Eligibility criteria:
inclusion criteria: * the onset duration more than 3 months * demonstration of brunnstrom stage equal to or above stage iii of the affected upper extremity * no serious cognitive deficits (a score of more than 24 on the mini mental state exam) * no serious visual and visual-perception impairments * no concurrent participation in other drug or rehabilitation research * no serious attention deficits * no excessive spasticity in any of the joints of the affected ul exclusion criteria exclusion criteria: * exhibit physician determined major medical problems or poor physical conditions that would interfere with participation * excessive pain in any joint that might limit participation

Keywords: comparative effectiveness research mirror therapy stroke rehabilitation clinical evaluation kinematic analysis mesh glove combined therapy
the effect of somatosensory cue on postural stability in blinded persons

Conditions: Visual Impairment

Summary: blind adults that willing to participate in the study will be tested with well-established measuring techniques of balance control using force plate in the movement and rehabilitation laboratory at ben-gurion university. an automated algorithm will be used to extract standardized stabilogram-diffusion parameters from each of the cop data sets collected during quiet standing. these parameters include diffusion coefficients, critical displacement, critical time and scaling exponents for both lateral and anterior-posterior sway directions (collins \& de luca, 1993). the subjects will be tested in 3 task conditions (eyes blindfolded, eyes blindfolded holding stick, eyes blindfolded holding a dog). participants will be required to stand on the platform 10 times for 30 s for each trial, they will be instructed to sway as little as possible.


Eligibility criteria:
inclusion criteria: * blind persons * able to stand safely for 30 seconds * able to walk independently * hip oa prior tha exclusion criteria: * stroke or other neurological diseases * orthopedic surgery at the past year
technologies to improve qol of prostate cancer

Conditions: Prostate Cancer

Summary: the m.i.o project, which stands for comprehensive oncological medicine, aims to comprehensively and multidisciplinary address the effects of prostate cancer, specifically in patients with hormone-sensitive metastatic prostate cancer (hsmpc), an advanced stage of the disease that still offers prolonged survival due to new medications. the proposal seeks to develop a healthcare approach that promotes self-care and improves the physical and mental health of patients. despite growing scientific evidence supporting an integrative approach in oncological care, the provision of personalized options for exercise, nutrition, and psychological therapy before, during, and after diagnosis remains limited. the project proposes to develop tools such as a dedicated mobile application that provides hsmpc patients access to various resources and therapies to improve their health, focusing on nutrition, exercise, and emotional well-being. m.i.o represents an innovative and holistic approach to addressing these patients' needs and improving their overall well-being. the main goal is to measure the quality of life of the application users through validated questionnaires in a randomized health education study to assess if there is a substantial improvement in their well-being.


Eligibility criteria:
inclusion criteria: * patients histologically diagnosed with prostate cancer * metastases confirmed by validated imaging studies * not meet criteria for castration resistance. exclusion criteria: * do not have a smartphone device * refuse to participate * not sign the informed consent.